STOCK TITAN

Jade Biosciences: RA Capital reports 2.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Jade Biosciences, Inc. (JBIO) is the issuer in an amended ownership report in which RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. each report beneficial ownership of 1,835,542 shares (2.9%) as of September 30, 2026. These reports concern the same Fund-held position, not four separate blocks.

The Fund directly holds the shares. Its narrative says it delegated voting and disposition authority to RA Capital, while the cover pages list shared voting and dispositive power over the reported amount for each reporting person. The Fund disclaims beneficial ownership because of the delegation; RA Capital, Kolchinsky and Shah disclaim it except for Section 13(d) purposes. The reported percentage is based on 63,597,387 shares outstanding as of August 3, 2026.

Beneficially owned 1,835,542 shares Each reporting person reported this amount as of September 30, 2026; the reports concern the same Fund-held position.
Percentage of class 2.9% Reported as of September 30, 2026, based on shares outstanding as of August 3, 2026.
Shares outstanding 63,597,387 shares As of August 3, 2026; used as the basis for the reported ownership percentage.
Delegation revocation notice 61 days The Fund says it may not revoke its delegation of voting and disposition power on less than 61 days' notice.
beneficial ownership regulatory
"aggregate number of shares ... beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 1,835,542.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 1,835,542.00"
Section 13(d) regulatory
"for purposes of Section 13(d) of the Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JBIO shares did the reporting persons report?

Each of the four reporting persons reported beneficial ownership of 1,835,542 shares, equal to 2.9% of the class, as of September 30, 2026. The reports concern the same position: RA Capital Healthcare Fund directly holds the shares, and the filing describes the related ownership and authority relationships.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





008064206

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:11/16/2026
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:11/16/2026
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:11/16/2026
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13[ ] filed with the SEC on October 16, 2025).

Keep reading